Bringing clarity to the concept of estimands and the key issues debated in E9(R1) will help industry experts to understand their purpose and impact on study design, statistical analyses and the study outcome.
The European Medicines Agency (EMA) adopted the E9(R1) addendum on estimands and sensitivity analysis in clinical trials effective July 30 2020. The E9 (R1) addendum presents a framework for defining an appropriate estimand for a clinical trial. OCT Clinical invites you to attend the webinar “E9(R1) Addendum on Estimands and Sensitivity Analysis. Considerations for Successful Implementation”, which is focused on considering the impact of, and documenting relevant intercurrent events within the estimand framework.
The webinar will be hosted by Kristina Bondareva, the Head of Biostatistics at OCT Clincal.
During the webinar you will learn about:
Who will benefit:
Learn more here
Register for the event: